Sorafenib Monotherapy In Patients With Metastatic Renal Cell Cancer: A Phase II Intra-Patient Dose Escalation Study

UroToday.com - Sorafenib 400 mg b.i.d. has shown anti-tumor activity and favorable tolerability in patients with metastatic renal cell carcinoma (RCC), allowing investigation of more intensive drug administration regimens. This titration study allowed individual patients to escalate to higher doses of sorafenib. Trial endpoints included response rate (RR), progression-free survival (PFS) and overall survival (OS).

More: continued here

Filed under: Cancer on April 13th, 2008